Remepy , a hybrid drugs developer secures $10million in seed funding . In addition to prior pre-seed lead investor TechAviv, Fresh.fund, Samsung Next, StageNext Fund, and 97212 Ventures, the round was headed by NFX and included Vine Ventures, PsyMed Ventures, Supernode Ventures, and Firstime Ventures.
Remepy is at the forefront of the development of hybrid pharmaceuticals, which mix traditional medications with personalised digital therapy to improve the efficacy of pharmacological treatments. The company is led by Dr. Michal Tsur and Or Shoval.
Read also – CA-based AiDash Secures $58.5Million in Series C Round Funding- FUNIDNG NEWS
Digital molecules are medicinal agents that act on the brain’s mechanisms of action, or MOAs, to produce physiological effects. It has been demonstrated that these physiological alterations increase the efficacy of conventional medications.
The business has already demonstrated the effectiveness of its medicines in human trials utilising blood and saliva samples, thorough brain imaging, and MCI, with encouraging outcomes for cancer, Parkinson’s disease, and MCI.
About Remepy
Remepy is a Leader in Hybrid PharmaceuticalsTM. They think that in the future, software programmes will be a crucial component of the therapies that pharmaceutical firms provide as Hybrid DrugsTM. These will influence patients through Hybrid Mechanisms of ActionTM, combining the effects of conventional drugs with software.
